Featured CIMIT Forum Topic: The New Economic Playbook for Healthcare
4.14.09 Forum Video & Slides:
Zen Chu on VC in Healthcare
4.14.09 Forum Videos:
Discussions with Panel and Audience
4.29.08 Forum Videos & Slides:
Zen Chu on Inventing High Impact & High Value Medical Therapies: Methods & Case Studies in Clinical Innovation
2007 Innovation Congress Video:
Venture Capital Panel Discussion
The goals of the "Innovation Grand Rounds" CIMIT Forum are to teach and share best practices for rapidly translating innovations into high impact clinical therapies, bridging academic research to the development and commercialization milestones necessary to bring important innovations to the patient bedside.
The meetings take place at the CIMIT Forum at various CIMIT Consortium hospitals in Boston and at the CIMIT Innovation Congress. Participants include innovative clinicians, life science researchers, entrepreneurial physicians, business executives and healthcare venture capital investors.
Presentation: The New Playbook for Healthcare Innovation Zen Chu, founder Accelerated Medical Ventures
Adapting to the challenges with early-stage innovation today
Startup opportunities given the current healthcare challenges
Methods to address the funding gaps for developing new innovations
Teams required to develop innovations through commercialization into new therapies
Roles for innovative physicians at each stage of the development lifecycle
Post a Comment
Panel: A panel of entrepreneurial MDs and entrepreneurs on the roles that physicians can play in the development of important new therapies -- from invention, through clinical proof, to new therapies that impact the standard of care.
Zen Chu, founder Accelerated Medical Ventures Michael Greeley, founder Flybridge Capital Partners Elazer Edelman, MD, PhD, Harvard Medical School, Highland Capital Joseph Smith, MD, PhD, VP, Emerging Technologies, Johnson & Johnson Marsha Moses, PhD, Children's Hospital Boston, Harvard Medical School, Predictive Biosciences
Panel Discussion: Realities of today’s economic situation
Panel Discussion: The capital gap, lack of liquidity in the markets,
and how to navigate to continue developing companies.
Panel Discussion: The checklist for investment, how parameters
for investment have changed, and how to clear early hurdles.
Questions from Audience to Panel: Setting the bar in medicine, global influence/innovation,
realities of bootstrapping, early stage seed money, SBIRs, and physician adoption/culture.
Panel Discussion Summary
The challenges and opportunities facing innovative companies are constantly changing, so it is important to keep track of trends in this business environment. The panelists offered numerous insights related to the current state of biomedical innovation.
Venture capitalists and large corporations have always been wary of making risky investments in long-term projects, and these projects have become even more unappealing to investors in recent months due to the economic downturn. Thus, innovators must choose their projects carefully so that the process of product development can be completed in a relatively short time.
Clinical trials are a major hurdle for which innovative companies must be prepared. For some products, such as drug-eluting stents, over ninety percent of development costs are related to clinical trials. Over the last few years, it has become easier for companies to outsource clinical trials in order to limit costs.
In today’s economy, credit is difficult to come by, so a number of biomedical companies are changing the way in which they do business. In the pharmaceutical industry, there have recently been a number of mergers, which are distracting and reflect a conservative approach to innovation. It is difficult for many scientists to find funding because national agencies do not have enough money to support any research beyond that which is related to fundamental science.
Successful innovation begins with the identification of a problem, not with the proposal of a solution. The initial solution to a problem is often not the best one, so companies must be willing and prepared to change their approach in response to new ideas. Economic difficulties might actually promote innovation by ensuring that only the best companies survive.
Inventing High Impact & High Value Medical Therapies: Methods & Case Studies in Clinical Innovation
Our evolving healthcare system is predicated on innovating new procedures and products to maximize the benefits to patient and society. Yet each specialty in medicine is a complex mix of current therapies, imperfect products, changing regulatory hurdles and reimbursement limitations. What are the critical success factors for innovations to reach the bedside and maximize clinical impact? How can physicians and researchers map current therapies and innovations that can reach broad adoption amid the economic challenges of our healthcare system?
This Forum will lend general summary of the process, best practices and pitfalls in clinical innovation and the commercialization process. An interactive panel discussion will include case studies and perspectives from the clinician inventor, entrepreneur, venture capital investor and corporate licensee.
Panel: Zen Chu, Accelerated Medical Ventures
Robert Creeden, Director, Partners Research Ventures David Milne, General Partner, SV Life Sciences Advisers Thomas Stossel, MD, American Cancer Society Professor, Department of Medicine,
Harvard Medical School, Co-Director, Division of Hematology, Brigham and Women's Hospital
2007 Venture Capital Panel Discussion
Our goal for this program is to create an opportunity for the Principal Investigator, researcher and science community to be exposed to venture capital aspects of business and investment decisions.
Panel: Michael A. Greeley, General Partner at IDG Ventures and President of NEVCA Bruce Booth, DPhil, Principal Atlas Venture Graham Gardner, MD, Senior Associate Highland Capital Partners Johnathan P. Gertler, MD, Managing Director Head of BioPharma Investment Banking Leerink Swann & Company James E. Muller, MD, CEO InfraReDx, Inc.